Sustained and rapid improvements in patient reported outcomes for moderate-to-severe psoriasis patients with moderate and high BSA treated with ixekizumab: Side-by-side results from UNCOVER-3 and IXORA-S

被引：0
|
作者：
Bagel, Jerry [1 ]
Gottlieb, Alice B. [2 ]
Burge, Russel [3 ,4 ]
See, Kyoungah [3 ]
Garrelts, Alyssa [3 ]
McKean-Matthews, Missy [5 ]
Papp, Kim [6 ]
机构：
[1] Psoriasis Treatment Ctr Cent NJ, East Windsor, NJ USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Syneos Hlth, Raleigh, NC USA
[6] Prob Med Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
26032
引用
收藏
页码：AB82 / AB82
页数：1
相关论文
共 50 条
  • [41] Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
    Honma, Masaru
    Cai, Zhihong
    Burge, Russel
    Zhu, Baojin
    Yotsukura, Sohiya
    Torisu-Itakura, Hitoe
    DERMATOLOGY AND THERAPY, 2020, 10 (06) : 1397 - 1404
  • [42] Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
    Masaru Honma
    Zhihong Cai
    Russel Burge
    Baojin Zhu
    Sohiya Yotsukura
    Hitoe Torisu-Itakura
    Dermatology and Therapy, 2020, 10 : 1397 - 1404
  • [43] Ixekizumab sustained complete clearance, itch resolution, and improved quality of life for moderate-to-severe psoriasis patients who achieved rapid, high skin clearance
    Rosmarin, David
    Gooderham, Melinda
    Ferris, Laura
    See, Kyoungah
    Wolf, Eric
    Burge, Russel
    McKean-Matthews, Missy
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB68 - AB68
  • [44] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) (vol 77, pg 855, 2017)
    Blauvelt, A.
    Gooderham, M.
    Iversen, L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 301 - 301
  • [45] Evaluation of the Psoriasis Skin Appearance and Bothersomeness (PSAB) measure in patients with moderate to severe psoriasis treated with ixekizumab compared to etanercept and placebo: Results from UNCOVER-2
    Luger, Thomas
    Gottlieb, Alice
    Puig, Lluis
    Nikai, Enkeleida
    Zhu, Baojin
    Heredia, Emily Edson
    Lin, Chen Yen
    Goldblum, Orin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB250 - AB250
  • [46] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER-2
    Griffiths, Christopher E.
    Reich, Kristian
    Lebwohl, Mark
    Van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Carlier, Hilde
    Cameron, Gregory
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta
    Ball, Susan
    Braun, Daniel
    Osuntokun, Olawale
    Heffernan, Michael
    Nickoloff, Brian
    Papp, Kim
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
  • [47] A Phase 3 Trial Comparing Ixekizumab with Placebo and Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from the 12 Week Induction Period of UNCOVER-2
    Griffiths, C. E. M.
    Leutz, A.
    Reich, K.
    Lebwohl, M.
    van de Kerkhof, P.
    Paul, C.
    Menter, A.
    Cameron, G. S.
    Erickson, J.
    Zhang, L.
    Secrest, R.
    Ball, S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Papp, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 3 - 3
  • [48] Impact of sustained robust response on patient-reported outcomes for adalimumab-treated patients with moderate to severe psoriasis: Subanalysis of REVEAL
    Strober, Bruce
    Sundaram, Murali
    Bao, Yanjun
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB194 - AB194
  • [49] Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
    Travaglini, Massimo
    Maul, Julia -Tatjana
    Kors, Christian
    Zaheri, Shirin
    Gerwien, Jens
    Mueller, Michaela
    Brnabic, Alan
    Sabatino, Silvia
    Schuster, Christopher
    Tsai, Tsen-Fang
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 2971 - 2983
  • [50] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
    Rui, Wenlong
    Li, Xia
    Zheng, Jie
    Pan, Weili
    Zheng, Min
    Lu, Yan
    Li, Fuqiu
    Ding, Yangfeng
    Zhang, Jianzhong
    Li, Hongying
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
12345